Alpha Teknova, Inc.
TKNOHealthcareNASDAQDrug Manufacturers - Specialty & Generic
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Alpha Teknova, Inc. focuses on Drug Manufacturers - Specialty & Generic services and products. Alpha Teknova, Inc. produces critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally. The company carries a $225.2M market cap, placing it firmly in the micro-cap category. The company' primary products include pre-poured media plates for cell growth and cloning; liquid microbial culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification.
Market Cap
$225.2M
Beta
0.63
P/E (TTM)
—
P/E (Fwd)
-17.14
EPS (TTM)
$-0.31
EPS (Fwd)
$-0.24
ROE
-23.9%
ROA
-9.3%
Cash
$17.8M
Total Debt
$27.8M
Free CF
-$2.4M
52W Change
-23.4%
Annual Financials
Cash vs Debt
On the balance sheet, TKNO has $17.8M in cash with $27.8M in obligations. The ability to service this debt comfortably depends on continued operational cash generation. The company is burning cash, with free cash flow at -$2.4M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -23.9%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has been relatively flat, moving from $41.4M (2022) to $40.5M (2025).
With a beta below 0.7, Alpha Teknova, Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Alpha Teknova, Inc. and its sector.